Semaglutide and Heart Health: The SELECT Trial Explained
GLP-1 medication is increasingly seen as cardiometabolic care, not just weight care. SELECT is why. Here is what it found, with honest framing.
What SELECT found
In the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023; PMID 37952131), semaglutide reduced the risk of major cardiovascular events such as heart attack and stroke by about 20% in relative terms. In absolute terms, the event rate was 6.5% with semaglutide versus 8.0% with placebo. That was in adults who had established cardiovascular disease along with overweight or obesity, and who did not have diabetes.
Why both numbers matter
A "20% reduction" sounds dramatic, and it is meaningful, but honest reporting gives you the absolute numbers too: 6.5% vs 8.0% over the study period. Both are true and both matter. The relative figure shows the size of the effect; the absolute figures show how it plays out across a population.
Ready to start?
$297 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialThe bigger cardiometabolic picture
Beyond SELECT, GLP-1 weight loss commonly improves blood pressure, triglycerides, blood sugar, and other risk factors together, because they share a root in excess weight and insulin resistance. That is why a supervised program tracks the whole picture with lab work, not just the number on the scale.
Frequently asked questions
Does semaglutide reduce heart attack and stroke risk?
In the SELECT trial (Lincoff et al., NEJM 2023, PMID 37952131), semaglutide reduced major cardiovascular events by about 20% in relative terms (6.5% vs 8.0% in absolute terms) in adults with established heart disease plus overweight or obesity, without diabetes. It is meaningful evidence for that specific population, not a guarantee for everyone, and it should be discussed with your physician in the context of your own health.
What does the 20% reduction actually mean?
It is a relative reduction: the event rate dropped from 8.0% on placebo to 6.5% on semaglutide over the study period. The 20% describes the size of the effect, and the 6.5% vs 8.0% shows the absolute rates. Honest reporting includes both, because the relative figure alone can overstate the everyday impact.
Do I need heart disease to benefit from a GLP-1?
No. SELECT studied a high-risk group, but GLP-1 weight loss commonly improves blood pressure, cholesterol, and blood sugar for many people as weight comes down, regardless of whether they have established heart disease. Whether a GLP-1 fits you is a medical decision based on your full health picture.
Is compounded semaglutide proven to protect the heart?
The SELECT evidence is for the brand-name medication in a specific population. Compounded semaglutide is not an FDA-approved or brand-identical product, and the trial is not a study of any specific compounded preparation. The honest takeaway is about the active ingredient and the cardiometabolic benefits of weight loss, confirmed by your physician with lab work.
Will my heart medications change on a GLP-1?
Possibly. As weight, blood pressure, and blood sugar improve, your physician may need to adjust blood-pressure, cholesterol, or diabetes medications. That is a physician's decision based on your labs and readings, and it is one reason this kind of care should be supervised rather than managed on your own.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.